calcimimetic

calcimimetic

Any drug that acts like calcium, for example, that lowers serum parathyroid hormone levels.

calcimimetic

Of any drug that increases activation of CALCIUM-SENSING RECEPTORS. Calcimimetics show promise in the treatment of hyperparathyroid states. Compare CALCILYTIC.
References in periodicals archive ?
2014) The odds of using phosphate binders, intravenous vitamin D analogs, and calcimimetic are higher among patients with low-income subsidies (OR = 1.
Strontium is a calcimimetic that blocks calcium ion channels.
In an appraisal consultation document, the National Institute for Health and Care Excellence (NICE) has recommended Amgen's (NASDAQ: AMGN) Parsabiv (etelcalcetide) to treat secondary hyperparathyroidism (sHPT), if treatment with a calcimimetic is indicated but cinacalcet is not suitable, and as long as the company provides the drug with the discount agreed in the patient access scheme, Pharma Times reported on Tuesday.
If approved, Parsabiv will be the first calcimimetic agent that can be administered intravenously by a healthcare provider three times a week at the end of a hemodialysis session.
Furthermore, only 2 patients were receiving cinacalcet, a calcimimetic agent, to decrease PTH and calcium levels.
Parathyroidectomy may now be necessary or expensive calcimimetic drugs must be administered to try to restore the disordered metabolic environment.
A calcimimetic (cinacalcet) is a new type of drug to be considered as a potential therapy for some people with severe hypercalcemia and primary hyperparathyroidism who are unable to undergo parathyroidectomy and for secondary hyperparathyroidism on dialysis.
Cinacalcet, a calcimimetic for control of hypercalcemia and secondary hyperparathyroidism, was also started.
Calcimimetic agents act as an allosteric modulator, imitating the properties of extracellular calcium activating the calcium-sensitive receptor on parathyroid cells.
Effects of the calcimimetic cinacalcet HCl on cardiovascular disease, fracture, and healthrelated quality of life in secondary hyperparathyroidism.
Cinacalcet is a calcimimetic drug, which lowers PTH without increasing calcium or phosphorus.
This finding diametrically changes the treatment strategy to controlling the effects of CKD on the cardiovascular system by decreasing the serum phosphorus and on the PTH concentration by using a calcimimetic agent, because the presence of hypercalcemia contraindicates increasing the dose of vitamin D analogs.